The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMP.L Regulatory News (AMP)

  • There is currently no data for AMP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Partner Company Update

1 May 2012 07:00

RNS Number : 4213C
Amphion Innovations PLC
01 May 2012
 



 

 

 

Amphion Partner Company, AXCESS, Receives Markman ruling in Savi Litigation

 

 

London and New York, 1 May 2012 - Amphion Innovations plc (LSE: AMP), announces that a Markman ruling was issued in case no. 3:10-cv-01033-F, Axcess International, Inc. (Axcess) vs. Savi Technology, Inc. (Savi) in the United States District Court for the Northern District of Texas, Dallas Division. Also announced is the trial date, now set for November 5, 2012.

 

Amphion Partner Company, Axcess International was issued a patent on September 25, 2001 entitled "High Sensitivity Demodulator for a Radio Tag and Method". The patent discloses a radio tag that uses circuitry capable of demodulating low powered analog carrier signals while drawing minimal current to improve the sensitivity and operational range of the radio tag while maintaining longer battery life. Axcess filed suit against Savi on May 21, 2010 accusing Savi's RFID tags of infringing 23 claims of the patent.

 

A "Markman" hearing is a pretrial hearing in a U.S. District Court during which a judge examines evidence from all parties on the appropriate meanings of relevant key words used in a patent claim, when patent infringement is alleged. Holding a Markman hearing in patent infringement cases has been common practice since the case of Markman v. Westview Instruments, Inc.. It was determined the language of a patent is a matter of law for a judge to decide, not a matter of fact for a jury to decide. Markman hearings are important, since the court determines patent infringement cases by the interpretation of claims.

 

Included in the Order were nine disputed and nine agreed-to claims. The Court construed each of the nine disputed claims in the ruling. The Court also resolved one of the parties' fundamental disputes about the scope of the patent. The Court said that the novelty of the invention was a new and improved tag to receive, process, evaluate, and respond to much weaker signals than such tags were capable of doing before, also increasing the operable life span of the radio tag as well as the distance over which the tag can operate.

 

"Having reached this important milestone, we now look forward to the trial in early November. We encourage interested parties to read the Order", said Allan Griebenow, President & CEO of Axcess International. "Axcess remains fully committed to the protection of this patent and others in our intellectual property portfolio."

 

While Amphion believes the above described ruling can be favorable to Axcess the ruling does not automatically mean that Axcess will prevail at trial. A copy of the Court's ruling can be downloaded from the Company's website at www.axcessinc.com.

 

As a result of additional investment in support of Axcess over the last few years, Amphion Innovations' holdings of equity and warrants now amount to about 14% of the fully diluted outstanding. In addition, Amphion holds approximately $1.8 million of debt, most of which is convertible into common stock.

 

 

 

 

For further information please contact:

 

Amphion Innovations

Charlie Morgan:

+1 (212) 210-6224

 

Cardew Group

Tim Robertson

+44 020 7930 0777

 

Seymour Pierce Limited, Nominated Adviser

Mark Percy/ Freddy Crossley:

+44 020 7107 8300

 

About Amphion Innovations plc

Amphion (LSE: AMP) builds shareholder value in emerging companies in the medical and technology sectors, by using a focused, hands-on company building approach, based on decades of experience in both the US and UK. Amphion has a significant shareholding in 7 Partner Companies developing proven technologies targeting substantial commercial marketplaces. The Amphion model has been refined to optimise the commercialisation of patents and other intellectual property within the Partner Companies. The Partner Companies collectively own or control over 200 separately identified pieces of intellectual property, a number which grows rapidly each year.

 

On the web: www.amphionplc.com

 

 

About Axcess International Inc.

Axcess International Inc. (OTCBB: AXSI) provides automated wireless identification solutions for business encompassing local location identification, tracking and control capabilities using its patented MicroWirelessTM technology platform. The complete system solutions supersede existing manual ID systems by automating various tasks that increase productivity, security, safety and business intelligence. MicroWireless - based on active RFID principles - is the economic and technological sweet spot for autonomously-powered low cost, miniature, remote wireless communication devices. Axcess is a portfolio company of Amphion Innovations plc (AIM: AMP). For more information on Axcess, visit www.axcessinc.com.

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAURUWRUKASOAR
Date   Source Headline
22nd Dec 20177:01 amRNSComment on Polarean Fund Raise
22nd Dec 20177:00 amRNSRestructure of Loan and Additional Drawdown
5th Dec 20177:00 amRNSIssue of Shares
23rd Nov 20177:00 amRNSFurther Update on Polarean Imaging Limited
10th Nov 20177:00 amRNSUpdate on Polarean Imaging Limited
2nd Nov 20177:00 amRNSOrder Dismissing DataTern Case
11th Oct 20177:00 amRNSRelated Party Transaction
5th Oct 20177:00 amRNSPartner Company releases positive clinical results
29th Sep 20177:00 amRNSHalf-year Report
25th Sep 20177:01 amRNSHolding(s) in Company
25th Sep 20177:00 amRNSSale of Partner Company Shares
30th Aug 20177:00 amRNSSale of partner company shares
30th Aug 20177:00 amRNSHolding(s) in Company
1st Aug 20175:19 pmRNSAGM Statement
28th Jun 20177:00 amRNSFinal Results
31st May 20177:00 amRNSPartner Company m2m Imaging merger update
22nd May 20174:36 pmRNSAdditional Draw Down on Loan Facility
7th Feb 20177:00 amRNSAdditional Draw Down on Loan Facility
1st Feb 20175:18 pmRNSHolding(s) in Company
30th Dec 20162:38 pmRNSHolding(s) in Company
16th Dec 20163:07 pmRNSDirector/PDMR Shareholding
9th Dec 20163:50 pmRNSDirector/PDMR Shareholding
24th Nov 20162:15 pmRNSHolding(s) in Company
8th Sep 20167:00 amRNSRe-negotiated terms of Motif CPN
7th Sep 20167:00 amRNSInterim Results for the six months to 30 June 2016
22nd Aug 20163:58 pmRNSAdditional Draw Down on Loan Facility
3rd Aug 20164:13 pmRNSHolding(s) in Company
29th Jul 20167:00 amRNSResults of AGM and Directorate Change
18th Jul 20164:33 pmRNSTransfer of Shares
13th Jul 20167:01 amRNSNotice of Intention to List on NASDAQ by Motif Bio
13th Jul 20167:00 amRNSAdditional Draw Down on Loan Facility
23rd Jun 20167:00 amRNSFinal Results
29th Apr 20164:02 pmRNSAdditional Terms on Loan Facility
28th Apr 20167:00 amRNSAdditional Draw Down on Loan Facility
7th Apr 20167:00 amRNSAmphion settles contested arbitration ruling
3rd Mar 20167:00 amRNSConvertible Promissory Note Extended
7th Jan 20167:00 amRNSDirectors' Dealings
5th Jan 20167:00 amRNSConvertible Promissory Note Terms Extended
26th Nov 20157:00 amRNSAdditional Draw on Loan Facility
5th Nov 20157:00 amRNSPartner Company m2m Imaging Corp. to merge
30th Oct 20154:20 pmRNSDeath of a Director - Replacement
30th Oct 20153:50 pmRNSDeath of a Director
17th Sep 20157:00 amRNSAmphion to present in London
16th Sep 20157:00 amRNSDirectors' Dealings
10th Sep 20157:00 amRNSDataTern Receives Favourable Ruling
3rd Sep 20157:00 amRNSInterim Results
28th Aug 20159:08 amRNSHolding(s) in Company
7th Aug 20155:15 pmRNSResult of AGM
22nd Jul 20154:32 pmRNSFDA QIDP Designation
22nd Jul 20157:00 amRNSFinal condition of £22m placing satisfied

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.